Xeljanz (Tofacitinib Citrate) Patent Expiration, LOE Window & CMS Spending

Xeljanz (Tofacitinib Citrate) by Pfizer: FDA Orange Book core substance LOE 2026-06-08 (last listed 2028-08-21), 12 AB generics, $404.2M 2024 CMS Part D & Medicaid spend, and 18 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPfizer
FDA Application & PathwayN203214 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2026-06-08
Last Listed Patent or Exclusivity Date2028-08-21
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors12
2024 CMS Total Public Spend$404.2M
2024 Medicare Part D Spend$273.8M
2024 Medicaid Spend$130.4M
Reported Wholesale Price Change (CA SB 17)18 WAC filings (max 17.3% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.